Slowing growth in emerging markets hits Nurofen maker Reckitt Benckiser as it misses sales expectations
Slowing growth in emerging markets hit consumer goods giant Reckitt Benckiser as it missed sales expectations.
The Durex and Nurofen maker reported like for like growth of 2 per cent in the third quarter.
Once its pharmaceuticals arm RB Pharmaceuticals, which the company is in the process of spinning off, is stripped out, sales rose by 3 per cent.
Slowing growth: The maker of Neurofen was impacted as warmer weather in Europe and the US saw fewer people stocking up on cold remedies
By this is still shy of the 3.7 per cent that analysts had expected.
The division, which analysts value at up to £2.5bn, will be sold by the end of the year, it said.
Reckitt also warned that the annual sales growth will be at the lower end of the company’s range, which is between 4 per cent and 5 per cent, amid slowing markets in southeast Asia and Latin America.
Total revenues for the quarter were £2.37bn, lower than the £2.43bn analysts had expected.
Consumer goods giants have been hit by stalling growth in emerging markets.
A quarter of Reckitt’s sales come from Asia Pacific and Latin America, and the group has been affected by Brazil’s slowing growth.
Chief executive Rakesh Kapoor said: ‘Looking ahead, our objective remains to deliver growth which outperforms our markets, although conditions will remain challenging.
'I continue to expect that the strength of our brands and the quality of our innovations will deliver our full year revenue targets.’
Jefferies analyst Martin Deboo said: ‘The market will view this as a modest disappointment. They’re being hurt by Brazil. That’s more of a market issue than a Reckitt-specific issue.’
Shares slipped 105p to 5010p.
Most watched Money videos
- German car giant BMW has released the X2 and it has gone electric!
- Tesla unveils new Model 3 Performance - it's the fastest ever!
- Iconic Dodge Charger goes electric as company unveils its Daytona
- How to invest for income and growth: SAINTS' James Dow
- Skoda reveals Skoda Epiq as part of an all-electric car portfolio
- Mini unveil an electrified version of their popular Countryman
- MG unveils new MG3 - Britain's cheapest full-hybrid car
- Steve McQueen featured driving famous stunt car in 'The Hunter'
- BMW meets Swarovski and releases BMW i7 Crystal Headlights Iconic Glow
- Land Rover unveil newest all-electric Range Rover SUV
- 'Now even better': Nissan Qashqai gets a facelift for 2024 version
- The new Volkswagen Passat - a long range PHEV that's only available as an estate
- PWC partners choose another man to become their next leader
- Sitting ducks: Host of British firms are in the firing...
- BUSINESS LIVE: Anglo American snubs BHP bid; NatWest...
- Anglo American snubs 'opportunistic' £31bn BHP bid
- UK cybersecurity star Darktrace agrees £4.3bn private...
- New private parking code to launch later this year that...
- NatWest follows rivals with profit slump
- LSE boss David Schwimmer in line for £13m pay deal...
- SMALL CAP MOVERS: Filtronic shares skyrocket following...
- BHP launches £31bn bid for Anglo American: Audacious...
- Sainsbury's takes a bite out of rivals: We're pinching...
- Anglo-American will not vanish without a fight, says ALEX...
- Unilever in talks with the Government about ice-cream...
- MARKET REPORT: Meta sheds £130bn value after AI spending...
- WPP revenues shrink as technology firms cut advertising...
- WH Smith shares 'more for patient money than fast bucks',...
- AstraZeneca lifted by blockbuster oncology drug sales
- Ten stocks to invest in NOW to profit from Rishi's...